Alta Partners VIII, L.P. 3
3 · SUTRO BIOPHARMA INC · Filed Sep 26, 2018
Insider Transaction Report
Form 3
Alta Partners VIII, L.P.
10% Owner
Holdings
Series C Preferred Stock
→ Common Stock (12,387,324 underlying)Series E Preferred Stock
→ Common Stock (18,698,578 underlying)Series B Preferred Stock
→ Common Stock (10,201,769 underlying)Series D Preferred Stock
→ Common Stock (9,449,318 underlying)- 0
No securities beneficially held
Series C Preferred Stock Warrant (right to buy)
Exercise: $0.48→ Series C Preferred Stock (671,997 underlying)
Footnotes (7)
- [F1]Each share of the issuer's Series B Preferred Stock will automatically convert into 0.0578 share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering ("IPO") and has no expiration date.
- [F2]The shares directly held by Alta Partners VIII, L.P. ("Alta VIII") are indirectly held by Alta Partners Management VIII, LLC ("Alta Management VIII"), which is the general partner of Alta VIII. The individual managing directors of Alta Management VIII are Farah Champsi, Guy Nohra and Daniel Janney. The managing directors of Alta Management VIII exercise sole voting and investment control with respect to the shares held by Alta VIII. The individual managing directors of Alta Management VIII disclaim beneficial ownership of all shares held by Alta VIII, except to the extent of their pecuniary interests therein.
- [F3]Each share of the issuer's Series C Preferred Stock will automatically convert into 0.0370 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date.
- [F4]Each share of the issuer's Series D Preferred Stock will automatically convert into 0.0405 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date.
- [F5]Each share of the issuer's Series E Preferred Stock will automatically convert into 0.0275 share of the issuer's Common Stock immediately upon the closing of the issuer's IPO and has no expiration date.
- [F6]The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised.
- [F7]The warrant has a net exercise provision under which the holder, in lieu of paying the exercise price in cash, can surrender the warrant and receive a net number of shares of preferred stock based on the fair market value of such stock at the time of exercise, after deducting the aggregate exercise price.